Biodexa Pharmaceuticals’ prospectus covers the resale of up to 170,150 ordinary shares, represented by 3,403 American Depositary Shares, by selling shareholders. For investors, the structure identifies a Shareholder resale rather than an issuer-led offering, while the securities are listed on the Nasdaq Capital Market under BDRX.

Key Highlights

  • Each ordinary share carries a nominal value of £0.000001.
  • Biodexa Pharmaceuticals registered the resale of up to 170,150 ordinary shares.
  • The ordinary shares are represented by 3,403 American Depositary Shares.

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) has registered the resale of up to 170,150 ordinary shares by selling shareholders. The ordinary shares are represented by 3,403 American Depositary Shares, making the transaction a shareholder resale rather than an issuer-led sale. The prospectus supplement is dated September 11, 2026.

170,150 Shares For Resale

The securities covered by the resale registration are ordinary shares with a nominal value of £0.000001 each. The prospectus supplement amends and supplements a prospectus dated March 30, 2026, and applies to the aggregate amount identified for resale by the selling shareholders. The registered securities are held within the shareholder resale structure.

3,403 ADS Representation

The 170,150 ordinary shares are represented by 3,403 American Depositary Shares. The transaction therefore covers both the underlying ordinary shares and their American Depositary Share representation.

Biodexa Pharmaceuticals’ securities remain identified for trading on the NASDAQ Capital Market under BDRX, while the registered sellers are the selling shareholders.